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Background: A meta-analysis was performed to systematically assess the diagnostic accuracy of vasodilator myocardial perfusion
cardiovascular magnetic resonance imaging (pCMR) and dobutamine stress echocardiography (DSE) for the detection of relevant
CAD. In contrast to previous work, this meta-analysis follows rigorous selection criteria in regards to the risk stratification and a
narrowly prespecified definition of their invasive reference tests, resulting in unprecedentedly informative results for this
reference group.
Data collection and analysis: From the 5,634 studies identified, 1,306 relevant articles were selected after title screening and
further abstract screening left 865 studies for full-text review. Of these, 47 studies fulfilled all inclusion criteria resulting in a total
sample size of 4,742 patients.
Results: pCMR studies showed a superior sensitivity 0.88 (95% confidence interval (CI): 0.85‐0.90) vs 0.72 (95% CI: 0.61‐0.81) ,
diagnostic odds ratio (DOR) 38 (95% CI: 29‐49) vs 20 (95% CI: 9‐46)  and an augmented post‐test probability negative
likelihood ratio (LR) of 0.14 (95% CI: 0.12‐0.18) vs 0.31 (95% CI: 0.21, 0.46)  as compared to DSE. Specificity was statistically
indifferent  0.84 (95% CI: 0.81‐0.87) vs 0.89 (95% CI: 0.83‐0.93) .
Conclusion: The results of this systematic review and meta-analysis suggest that pCMR has a superior diagnostic test accuracy for
relevant CAD compared to DSE. In patients with intermediate risk of CAD only pCMR can reliably rule out relevant stenosis. In this
risk cohort, pCMR can be offered for initial risk stratification and guidance of further invasive treatment as it also rules in
relevant CAD.
  
 Contribution to the field
The evaluation of the accuracy of pCMR and DSE for diagnosis of significant coronary artery stenosis is relevant for the
appropriate management and risk stratification of patients with suspected or stable CAD. Erroneous interpretations of
hemodynamic relevance of stenosis can lead to clinically unnecessary revascularizations without any prognostic benefit to patients.
Moreover, the underlying systematic review revealed a discrepancy between the absolute amount of evidence on DSE assessment
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Key Points 24 
Question: Which imaging modality for initial risk stratification of patients with an 25 
intermediate pre-test probability of CAD is superior? 26 
Findings: In this systematic review and meta-analysis the diagnostic accuracy of pCMR 27 
and DSE was systematically assessed in 47 studies reporting data from 4,742 patients. 28 
The findings suggest that pCMR has a superior test accuracy compared to DSE in the 29 
detection of relevant CAD (sensitivity 0.88 vs 0.72, specificity 0.84 vs 0.89). 30 
Meaning: Despite the widespread use of DSE, the evidence at hand favours pCMR in 31 
the risk stratification of patients with an intermediate risk of CAD.  32 
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Structured abstract  33 
Objectives: Guideline recommendations for patients with either a high or a low risk of  34 
obstructive coronary artery disease (CAD) are clear. However, the evidence for initial 35 
risk stratification in patients with an intermediate risk of CAD is still unclear, despite the 36 
availability of multiple non-invasive assessment strategies. The aim of this study was 37 
to synthesize the evidence for this population to provide more informed 38 
recommendations.  39 
Background: A meta-analysis was performed to systematically assess the diagnostic 40 
accuracy of vasodilator myocardial perfusion cardiovascular magnetic resonance 41 
imaging (pCMR) and dobutamine stress echocardiography (DSE) for the detection of 42 
relevant CAD. In contrast to previous work, this meta-analysis follows rigorous 43 
selection criteria in regards to the risk stratification and a narrowly prespecified 44 
definition of their invasive reference tests, resulting in unprecedentedly informative 45 
results for this reference group. 46 
Data collection and analysis: From the 5,634 studies identified, 1,306 relevant articles 47 
were selected after title screening and further abstract screening left 865 studies for 48 
full-text review. Of these, 47 studies fulfilled all inclusion criteria resulting in a total 49 
sample size of 4,742 patients.  50 
Results: pCMR studies showed a superior sensitivity [0.88 (95% confidence interval 51 
(CI): 0.85-0.90) vs 0.72 (95% CI: 0.61-0.81)], diagnostic odds ratio (DOR) [38 (95% 52 
CI: 29-49) vs 20 (95% CI: 9-46)] and an augmented post-test probability [negative 53 
likelihood ratio (LR) of 0.14 (95% CI: 0.12-0.18) vs 0.31 (95% CI: 0.21, 0.46)] as 54 
compared to DSE. Specificity was statistically indifferent [ 0.84 (95% CI: 0.81-0.87) vs 55 
0.89 (95% CI: 0.83-0.93)].  56 
Conclusion: The results of this systematic review and meta-analysis suggest that 57 
pCMR has a superior diagnostic test accuracy for relevant CAD compared to DSE. In 58 
patients with intermediate risk of CAD only pCMR can reliably rule out relevant 59 
stenosis. In this risk cohort, pCMR can be offered for initial risk stratification and 60 
guidance of further invasive treatment as it also rules in relevant CAD.  61 
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 1 
Abbreviation list 65 
CAD  Coronary artery disease  66 
CCA  Conventional coronary angiography  67 
CI  confidence interval (CI) 68 
DSE  Dobutamine stress echocardiography  69 
DTA   Diagnostic Test Accuracy  70 
DOR   Diagnostic odds ratio  71 
FFR  Fractional flow reserve  72 
FP  False positive 73 
FN  False negative 74 
LR   Likelihood ratio  75 
MDCT Multi-detector computer-tomography 76 
pCMR  Perfusion cardiovascular magnetic resonance 77 
HSROC Hierarchical summary receiver operating characteristic 78 
SPECT  Single-photon emission computed tomography 79 
MDCT Multidetector computed tomography 80 
MI  Myocardial infarction 81 
TP  True positive 82 
TN  True negative 83 
QUADAS Quality Assessment of Diagnostic Accuracy Studies tool 84 
  85 
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Myocardial ischemia in the form of relevant coronary artery stenosis is strongly 87 
associated with adverse outcomes such as myocardial infarctions (MIs) and death.(1) 88 
An early and accurate identification of myocardial ischemia has consequently been 89 
highlighted as a priority in current international guidelines.(2, 3) Conventional coronary 90 
angiography (CCA) or a fractional flow reserve (FFR)-based assessment is the 91 
reference standard for diagnosis of CAD in patients with a high pre-test probability. An 92 
non-invasive assessment with multi-detector CT-angiography (MDCT) is the preferred 93 
approach in patients with a low pre-test probability of CAD.(3) 94 
However, in the large number of patients with an intermediate pre-test probability, 95 
guidance is underdeveloped on which of the different non-invasive imaging modalities 96 
is to prefer and clear recommendations are not yet available.(2, 3) Myocardial 97 
perfusion cardiovascular magnetic resonance imaging (pCMR), dobutamine stress 98 
echocardiography (DSE), or alternative techniques can be performed equivalently for 99 
a non-invasive functional assessment of myocardial ischemia in this risk cohort.(4) 100 
Therefore, there is a strong need to identify the best diagnostic alternative for these 101 
patients.  102 
In this systematic review and meta-analysis, pCMR and DSE have been selected 103 
because they are the only imaging modalities without radiation and are frequently 104 
operated by cardiologists alone. Moreover, a diagnostic superiority over Single Photon 105 
Emission Computed Tomography (SPECT) in the detection of relevant coronary 106 
stenosis, for instance, has already been shown in several meta-analyses,(4, 5) and 107 
trials, such as the CE-MARC, MR-IMPACT I and II.(6, 7) Most recently, the MR-108 
INFORM trial even suggested that pCMR is “noninferior to FFR with respect to major 109 
adverse cardiac events” in stable patients with high risk of CAD, underlining its 110 
significance in the non-invasive assessment of CAD.(8) 111 
Several systematic reviews and meta-analyses have been published on the diagnostic 112 
accuracy of various imaging approaches.(4, 5, 9) However, the ability of these meta-113 
analyses to support clinical decission making is potentially limited due to considerable 114 
heterogeneity between their included studies. This heterogeneity is due to broad 115 
eligibility criteria, varying reference tests and comparators, and vague definitions of 116 
“significant coronary artery stenosis”. (5) Most importantly though, heterogeneity is due 117 
to individual patient risk for CAD in the included study cohorts, such as age, sex and 118 
different risk factors. Studies with verification bias and studies from unsystematic 119 
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 3 
literature searches are included in some of these analyses, which influences their 120 
applicability. Finally, previous meta-analyses have not employed systematic search 121 
methods, resulting in an incomplete or invalid identification of the available evidence. 122 
Each of these limitations of existing evidence reduces their ability to make 123 
recommendations for specific populations in the context of guideline development and 124 
as such there are still evidence gaps in the literature. 125 
To address these existing evidence gaps, we performed a systematic review and meta-126 
analysis with rigorous eligibility criteria on risk stratification and reference procedures, 127 
ascertaining the diagnosis of hemodynamically significant CAD. We focused on pCMR 128 
and DSE with the aim of providing resilient recommendations for the large number of 129 
patients with an intermediate risk of CAD.   130 
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Methods  131 
Registration 132 
This systematic review and meta-analysis was prospectively registered in PROSPERO 133 
under the registration number CRD42018105535. Reporting of the systematic review 134 
has been performed according to the PRISMA statements(10) and the Cochrane 135 
Handbook for Systematic Reviews of Diagnostic Test Accuracy (DTA).(11) The search 136 
was conducted in July 2018 and the latest included study was published in May 2018.  137 
 138 
Inclusion and exclusion criteria  139 
Peer-reviewed studies were included in the analysis if pCMR and/or DSE were used 140 
to identify relevant coronary artery stenosis in patients at the age of 18 years and above 141 
with non-diagnosed or stable, asymptomatic CAD without ischemia-associated ECG 142 
abnormalities (right/left bundle branch block) and preserved left-ventricular ejection 143 
fraction. Only studies that included CCA and/or FFR as the reference test have been 144 
selected and sufficient detail to reconstruct a contingency table (e.g. true positive (TP), 145 
false positive (FP), false negative (FN), and true negative (TN) findings) was also 146 
needed. For pCMR, studies needed to use either adenosine or regadenoson perfusion 147 
with a qualitative or semi-quantitative approach and reports of CMR with dobutamine 148 
were not included. For DSE only studies with transthoracic assessment evaluating wall 149 
motion abnormalities were included. 150 
Studies on animals, studies with fewer than 20 patients, and studies reporting data on 151 
patients with unstable angina, acute or subacute MI, heart transplantation, acute 152 
coronary revascularization, congenital or ischemic heart disease were excluded. Any 153 
studies using only physical stress, echo perfusion imaging or non-visual assessment 154 
were excluded. Studies with a different definition of relevant CAD determined by CCA 155 
and FFR were excluded, such as grade of stenosis <70% or a value >0.80 on FFR 156 
recordings.(2) Studies on microvascular disease were also excluded. Studies in a 157 
language other than English, French or German were excluded. 158 
 159 
 160 
Search methods for identification of studies 161 
For the systematic review, MEDLINE (1946 to July 29, 2018), EMBASE (1974 to July 162 
29, 2018) and Cochrane Library (Cochrane Database of Systematic Reviews: Issue 7 163 
of 12, July 2018) databases were searched for articles that met inclusion criteria. 164 
In r v
i w
         
 
 5 
Additionally, references of other meta-analyses published on the topic have been 165 
screened for further studies. 166 
We developed a sensitive search strategy for MEDLINE (Ovid Web), EMBASE (Ovid 167 
Web) and the Cochrane Library (Wiley Online Library) as recommended in the 168 
Cochrane Handbook for Systematic reviews of DTA. The search strategy is shown in 169 
full in the supplementary material.  170 
 171 
 172 
Data collection and analysis  173 
Selection of studies 174 
Two investigators (SMH and SIH) independently reviewed first article titles, then 175 
abstracts and finally the full text for eligibility. Discrepancies were resolved by 176 
discussion and consequent consensus. 177 
 178 
Data extraction and management 179 
For each study, both investigators (SMH and SIH) independently extracted information 180 
on author, year of publication, imaging technique, study size, demographic 181 
characteristics of participants (mean age, percentage male), magnetic field strength, 182 
type of stressor, type of assessment (qualitative or quantitative), definition of relevant 183 
CAD, prevalence of CAD and the presence of risk factors (diabetes, hypertension), the 184 
clinical settings considered (suspected or known CAD), as well as the numbers of TP, 185 
FP, FN and TN. Discrepancies between investigators extraction were resolved by 186 
consensus after discussion. 187 
If studies reported data for multiple CAD definitions (for instance at >50 %, >70% and 188 
>90 % stenosis), only the sensitivity of the cut-off point that was the closest to our 189 
definition (e.g. >70%) was extracted. If a study reported sensitivity and specificity 190 
measures of multiple observers, the mean values were used. Patient characteristics 191 
extracted from all studies included in this meta-analysis are weight-adjusted averages; 192 
the weights have been based on the study size. 193 
 194 
Assessment of methodological quality 195 
The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool,(12) 196 
recommended in the modified version suggested by the Cochrane Handbook for 197 
Systematic reviews of DTA (13) was used to assess the quality of included studies. 198 
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 6 
Two investigators (SMH and SIH) independently examined the study quality of the 199 
included reports. Disagreement was resolved by discussion and subsequent 200 
consensus. 201 
 202 
Statistical analysis and data synthesis 203 
For all included studies sensitivity, specificity, positive likelihood ratio (LR), negative 204 
LR, and diagnostic odds ratio (DOR) with 95% confidence interval (CI) were calculated 205 
from the TP, FP, FN and TN results. Hierarchical models, recommended by the 206 
Cochrane DTA reviews, (14) include the interdependence of sensitivity and specificity 207 
observed across studies which may alter their true effect size. Since an explicit cut-off 208 
point for relevant coronary artery stenosis was pre-defined in this meta-analysis, the 209 
Bivariate model by Reitsma (13) has been applied to produce summary operating 210 
points of sensitivity and specificity directly.  211 
Statistical analysis was performed with Stata software version 15.0 (StataCorp LLC, 212 
College Station, Texas, USA). A two-tailed p value of < 0.05 was considered to be 213 
significant, unless otherwise stated.  214 
 215 
Investigations of heterogeneity 216 
One major cause of heterogeneity in test accuracy studies is the threshold effect.(9) 217 
Therefore, only studies with the same reference value of relevant coronary stenosis 218 
are incorporated in this meta-analysis. Regardless, a meta-regression analysis has 219 
been facilitated to study potential reasons of heterogeneity in form of sex, age, sample 220 
size, MRI field strength, demographic patient characteristics, prevalence of CAD and 221 
several cardiovascular risk factors, as well as the reference method (CCA vs FFR).  222 
In-between study heterogeneity has been evaluated using the Cochrane-Q test (with 223 
a p value of < 0.10 contemplating significant heterogeneity) and the I2 statistic.(15)  224 
 225 
Sensitivity analyses 226 
Pooled estimates of sensitivity and specificity with a 95% CI have been combined 227 
independently across all studies using a random effect meta-analysis that takes into 228 
account the possibility that these estimates may actually differ in-between studies, as 229 
a result of clinical and methodological differences.(15) The value of LRs allows to 230 




         
 
 7 
Assessment of reporting bias 233 
To explore publication bias, a funnel plot of the natural logarithm of the diagnostic odds 234 
ratio was constructed and a regression test for asymmetry was performed weighted to 235 
the study size.(17) The threshold of significance was set to a p value < 0.10 for this 236 
method.  237 
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Literature search 239 
The systemic search identified 5,634 potentially relevant articles. After removal of 240 
duplicates and screening study titles, 1,306 articles were retained. These articles were 241 
screened by abstract and after 441 articles were excluded, the full texts of 865 articles 242 
were reviewed. Of these, forty-seven studies were judged as eligible for the meta-243 
analysis.  244 
The flowchart of the article search and selection process is illustrated in Figure 1. 245 
 246 
Methodological quality of included studies  247 
Quality assessments using the QUADAS tool assessment can be found in the 248 
supplementary material. 249 
 250 
Study characteristics 251 
A total of 47 studies with 4,742 patients, published between 1993 and 2018, were 252 
included in this meta-analysis: 39 pCMR (4,115 patients), 9 DSE (652 patients). One 253 
of these 47 studies, Kamiya et al.,(18) reported both pCMR and DSE results, thus both 254 
sets of data contribed to the quantitative assessment. The systematic literature search 255 
initially identified more DSE studies (3,752 vs 2,174) on the topic, however, the rigour 256 
of study design was generally inferior, so that only 0.2% as compared to 1.8% for 257 
pCMR studies fulfilled all of our strict inclusion criteria. The sample size varied from 24 258 
to 676 patients. Results showed that 50% of patients (2,359 of 4,692) had 259 
hemodynamic relevant CAD (Table 1). The study populations had a mean age of 61 260 
years and the majority of patients were men (64% of all patients). In most studies 261 
patients were hypertensive (60% of all patients) with some having additional risk 262 
factors such as diabetes (21% of all patients).  263 
 264 
Diagnostic accuracy 265 
Pooled estimates of sensitivity, specificity, positive and negative LR, as well as DOR 266 
are summarized in Table 2. The data of all studies are summarized in forest plots 267 
(Figure 2 and 3) and summary estimates of sensitivity and specificity for pCMR and 268 
DSE are stated with a 95 % CI.  269 
At the patient level, pCMR (0.88, 95% CI: 0.85–0.90) had higher sensitivity compared 270 
to DSE (0.72, 95% CI: 0.61–0.81). Conversely, specificity of DSE (0.89, 95% CI: 0.83–271 
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0.93) was statistically non-superior compared to pCMR (0.84, 95% CI: 0.81–0.87), as 272 
described in Figure 2 and 3. The DOR was highest for pCMR (38, 95% CI: 29–49) as 273 
compared to DSE (20, 95% CI: 9–46). (see Table 2) At a low clinical likelihood (pre-274 
test probability 25%), both test fail to sufficiently rule-in (defined as post-test probability 275 
>85%) obstructive CAD (pCMR 65% CI: 63-67% vs DSE 68% CI: 62-74%). (Figure 4 276 
B) In a patient with a very high likelihood (pre-test probability 75%) of CAD on the other 277 
hand, ruling out relevant stenosis (defined as post-test probability <15%) becomes 278 
challenging when post-test probability ranges from CI: 26-35% for pCMR and CI: 39-279 
58% for DSE studies. (Figure 4 C) In the intermediate risk cohort, however, with a pre-280 
test probability of 50%, solemly an pCMR-based assessment could sufficiently rule-in 281 
and rule-out obstructive CAD with a post-test probability of 85% (CI: 83-86%), 282 
respectivley 13% (CI: 12-14%), compared to DSE-based assessment with 86% (CI: 283 
83-90%), and 24% (CI: 21-28%). 284 
Hints for heterogeneity were found for the sensitivity of pCMR (Q=113.2, p<0.01; I2=66, 285 
95% CI: 55–78), and for the specificity results across studies (Q=140.6, p<0.01; I2=73, 286 
95% CI: 64–82). DSE also showed heterogeneity for sensitivity (Q=24.9, p<0.01; I2=68, 287 
95% CI: 45–90) and for specificity (Q=21.1, p<0.01; I2 =72, 95% CI: 34–90) (see Figure 288 
2 and 3). The forest plots further highlights three potential outliers for pCMR studies 289 
Klem (2006), Costa (2007), Scheffel (2010) and a single potential outlier, Santoro 290 
(1998), for DSE studies. A sensitivity analysis is shown in the supplementary material 291 
in which the influence of these studies on the summary estimates is assessed.  292 
 293 
 294 
Heterogeneity assessment 295 
The meta-regression analysis was used in order to reveal factors impacting 296 
heterogeneity incorporated sex, age, MRI field strength, prevalence of CAD and 297 
cardiovascular risk factors, as well as the reference method (FFR vs CCA). No 298 
parameter was identified as a significant predictor of heterogeneity for pCMR studies. 299 
For DSE studies, meta-regression analysis suggested that the prevalence of diabetes 300 
(p<0.01) was an independent predictor of heterogeneity (see Figure 5). 301 
In a subgroup analysis to identify reasons for in-between study variation and to 302 
investigate if the distribution of specific study characteristics biased the comparison of 303 
the two imaging methods, no significant effect of study and test characteristics was 304 
found on the DTA performance. A trend towards a lower diagnostic accuracy of pCMR 305 
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studies performed at 1.5 T as compared to 3.0 T scanners was seen but was not 306 
significant. For DSE, studies with a higher prevalence of diabetes were associated with 307 
a worse diagnostic performance. The diagnostic accuracy of pCMR in comparison to 308 
DSE remained unaffected in the majority of subgroup analyses (see Figure 5). 309 
Surprisingly, the diagnostic accuracy of pCMR studies was not affected by the 310 
reference method, whereas DSE studies showed a tendency towards a lower 311 
sensitivity when using FFR rather than CCA as reference. This might hint an advantage 312 
of pCMR for the hemodynamic assessment of coronary stenosis over DSE, even 313 
though the differences did not reach a statistical significant level (see Figure 5). 314 
A more in depth analysis of  heterogeneity can be in the supplementary material.  315 
 316 
Bias assessment 317 
In the assessment of publication bias, the slope coefficient for pCMR suggests 318 
symmetry in the data and therefore a low likelihood of publication bias with a 319 
statistically non-significant p-value of 0.95 (see supplementary material Figure 6 A). 320 
However, the slope in the DSE Deek’s funnel plot (see Figure 6 B) is suggestive of a 321 
bias from small studies even if the p-value is not significant (0.74).   322 In r v
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The present meta-analysis demonstrates that pCMR has a significantly higher 325 
diagnostic accuracy in detecting obstructive CAD than DSE in stable patients with an 326 
intermediate risk of CAD. Here, only an assessment with pCMR can rigourusly rule-in 327 
and rule-out relevant stenosis. Therefore, this meta-analysis can inform clinical 328 
decision making regarding interventional coronary therapy in the intermediate risk 329 
cohort. Despite the presently high utilization of DSE for non-invasive assessment of 330 
CAD especially in European facilities, the evidence for that is supported by studies of 331 
inferior quality and study populations with divers risk stratification.(19) From the 3,752 332 
studies initially identified by the systematic literature review for DSE in this meta-333 
analysis, only nine studies (0.2%) had a high quality study design and fulfilled all 334 
inclusion criteria. This is a small sample of the available evidence on DTA of one of the 335 
oldest stress tests used in clinical practice to detect obstructive CAD. However, the 336 
broad body of evidence regarding DTA of DSE is very diverse in the sense of blended 337 
with comorbidities and preconditions, that we excluded in our very precise selection 338 
process in order to perfectly depict patients with an intermediate risk of CAD.(20) Most 339 
studies had varying reference standards, unclear cut-off values of relevant stenosis, 340 
limited contemporary data, fewer comparisons to FFR or did not recruit a homogenous 341 
patient collective.(4, 5) Less strict inclusion criteria would have allowed a larger 342 
proportion of studies to be included in the assessment of DTA of DSE, leading to more 343 
heterogeneity in-between studies and thus an overall wider confidence of respective 344 
results. By focussing on DSE and excluding studies with dypiridamole and/or 345 
adenosine stress-echocardiography we choose the modality with the highest 346 
diagnostic accuracy over its competitors at the expanse of a broader base of studies 347 
to include in our meta-analysis. This results in less heterogeneity, a less diluted and 348 
thus more comparable precision of DTA. However, the novelty of this meta-analysis is 349 
the assessment of a well-defined and very precise cohort of patients with an 350 
intermediate pre-test probability of CAD. Inclusion of studies with patients of other risk 351 
cohorts would have biased the results and falsified the interpretation of DTA for 352 
patients at an intermediate risk of CAD. Consequentley, our results precisely depict 353 
the DTA of pCMR and DSE for patient at an intermediate pre-test probability of CAD 354 
and cannot automatically be generalised to patients at other risk levels. Providing 355 
higher quality evidence on DSE  is critical for clinical decision making and these issues 356 
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should be adressed in large scale comparative-effectiveness trials, in order to reassess 357 
diagnostic recommendations.(19)  358 
The recent results of the ISCHEMIA trial put the necessity of testing for obstructive 359 
CAD in patients with intermediate risk in question.(21) Arguably, this trial rather 360 
highlights the strong medical need to identify the optimal diagnostic test modality in 361 
this risk cohort, rather than making it obsolete. Since the identification of patients, 362 
where the benefits from invasive procedures outweigh the risks is essential, the results 363 
of our meta-analysis can guide clinical decision making in patients with an intermediate 364 
risk of obstructive CAD. The reservation must be made, however, that the non-invasive 365 
assessment in the ISCEHMIA trial was facilitated by MDCT, which can be susceptible 366 
to overestimating stenosis in specific patients.(22) The non-inferiority of a strictly 367 
conservative vs an invasive management could also be explained in part by a 368 
suboptimal identification of obstructive CAD, underlining the relevance of the evidence 369 
collated in this work. 370 
Whilst not all commonly employed perfusion tests, such as SPECT, PET or FFRCT 371 
were included in this analysis, previous meta-analyses have suggested SPECT (DOR 372 
9.1, 15.3) is less accurate than DSE (DOR 9.5, 26.3) and pCMR (DOR 92.2, 26.4) for 373 
the detection of relevant coronary stenosis.(4, 5) However, more recent results from 374 
the EVINCI study, where a comparison between wall motion and myocardial perfusion 375 
imaging was performed in patients with stable chest pain and intermediate likelihood 376 
of CAD, demonstrate that the diagnostic accuracy of the latter was similar to that of 377 
DSE.(23) It should be noted that perfusion imaging is predominately performed by 378 
SPECT in the USA, comprising around 90% of stress tests anually.(24)  379 
However, our findings cannot be generalised to other scenarios with patients at 380 
different pre-test probabilities or compared with myocardial perfusion tests not inlcuded 381 
in this assessment. Symptomatic patients with unstable disease or a high risk of CAD 382 
were excluded in this analysis because guidelines for this group are clear and 383 
supported by a large body of existing evidence. (2, 3) Despite, the recently published 384 
results of the MR-INFORM trial provide evidence of non-inferiority of pCMR as 385 
compared to FFR in the symptomatic patient cohort with high risk of CAD, which might 386 
even influence future guideline recommendations in favour of pCMR.(8) Nevertheless, 387 
current guidelines recommand non-invasive assessment strategies with MDCT in 388 
patients at low risk of obstructive CAD, since in this cohort perfusion tests failed to 389 
sustainably rule-out obstructive disease.(2, 3) 390 
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In this meta-analysis, a non-inferior diagnostic accuracy of pCMR in the subgroup of 391 
diabetic patients could hint a relevant diagnostic advantage in patients with low event 392 
rates. On the contrary, DSE studies had an inferior diagnostic performance in this 393 
subgroup, which is inline with findings from the DIAD trial(25) and the work of Bax and 394 
colleagues,(26) where the screening for CAD in asymptomatic, diabetic patients was 395 
ineffective given a low event rate. Nonetheless, current guidelines for symptomatic 396 
patients with a low risk for CAD are favouring MDCT for initial assessment, even 397 
though studies provide evidence of non-inferiority only to standard care and over a 398 
limited follow-up period of 6 months.(3, 22) Results from this meta-analysis confirm a 399 
statistically insufficient risk startification in patients with low event rates with an non-400 
invasive pCMR or DSE-based assessment.  In consequence, these data emphasize 401 
the role of non-invasive imaging to guide clinical decision making and highlight the 402 
indisputable need for a distinct recommendation on the diagnostic work-up of patients 403 
with an intermediate risk of CAD.  404 
 405 
 406 
Strengths and weaknesses of review  407 
The findings of this meta-analysis are novel and expand on previous studies.(4, 5, 9) 408 
In contrast to previously published studies on DTA of obstructive CAD we like to 409 
emphasize that the results of our meta-analysis depict the clinically particularly relevant 410 
cohort of patients with an intermediate pre-test probability. Furthermore, we excluded 411 
studies that pre-selected their patients on the basis of angiographic findings to 412 
investigate the accuracy of the imaging modalities to identify obstructive CAD, rather 413 
than the ability to verify angiographic findings. This distinguishes our approach from 414 
the findings of the PACIFIC study for instance.(27) Since the scope of our study was 415 
a patient- rather than a vessel-based assessment of DTA, our findings can be regarded 416 
as complementary to the results of the EVINCI trial, focusing on co-localization of 417 
perfusion defects with angiographic findings in patients also with an intermediate risk 418 
of CAD.(23) In addition, a pre-defined, invasive cut-off value for diagnosis of relevant 419 
coronary artery stenosis has been applied so that we could compare more similar 420 
populations with less heterogenous results. This differentiates our work from previous 421 
meta-analysis. Specifically, FFR as well as CCA were used as reference standards 422 
with their respective cut-offs from international guidelines.(2, 3, 28)  423 
CCA cannot always provide sufficient information on the hemodynamic significance of 424 
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a coronary artery stenosis, as the landmark trials FAME(29) as well as FAMOUS-425 
NSTEMI(30) have shown. Nevertheless, “diffuse coronary atherosclerosis without 426 
focal stenosis at angiography”(31) can cause a continuous pressure fall along the 427 
vessel length, “due to increased rest-perfusion, hence a lower flow-reserve”(31) and 428 
this can lead to FFR values below the ischemic threshold, even in the absence of 429 
relevant CAD.(31) Due to these issues, the analysis in this study was not restricted to 430 
reports that performed only FFR with the aim of avoiding confounding related to a 431 
narrow endpoint. In addition, studies that compared pCMR exclusively to FFR, 432 
sensitivity and specificity for the diagnosis of functionally relevant CAD has been 433 
significantly higher than in studies where it was compared with CCA only.(32) This 434 
could be due to confounding of non-flow limiting stenosis in studies using CCA as the 435 
reference test with hemodynamically insignificant cut-off values. This meta-analysis 436 
incorporated only studies with severe definitions of significance for coronary artery 437 
stenosis (lumen narrowing of >70% in CCA).(2) 438 
A key strength of this study is that a more comprehensive and detailed search strategy 439 
was used than in existing meta-analyses,(4, 5, 9) meaning that the present study has 440 
a higher chance of identifying all available literature on the aimed risk cohort. For 441 
example, a similar published meta-analysis by Danad et al. (2017) reported data 442 
comparing several myocardial perfusion tests but did not use a systematic review of 443 
the literature nor a specific patient risk stratification.(4) They included only three studies 444 
on DSE and four pCMR studies as compared to the nine DSE and 39 pCMR studies 445 
included in this review. This supports the argument that more comprehensive methods 446 
were able to identify a wider range of existing work.(4) Another strength is that while 447 
prior syntheses have included studies that have been evaluated with reference tests 448 
that comprised FFR and CCA assessments at different cut-off points,(5) this study 449 
reports at specific thresholds which minimizes risk of bias.(14) On that note, studies 450 
that only used FFR measurements were largely single centre and small trials. Patients 451 
were often pre-selected due to their angiographic findings, which may also improve 452 
sensitivity at the cost of specificity. These circumstances thus alter the generalizability 453 
of results and present another reason for incorporating both, CCA and FFR, reference 454 
standards as was done in this study. Even though a higher sensitivity but a lower 455 
specificity was seen in pCMR studies, which predominately used FFR measurements 456 
as the reference standard, the meta-regression and sub-group analysis of this report 457 
attested no confounding of preselection. To elaborate on that, reporting  different cut-458 
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off values for FFR (e.g. 0.75 or 0.70) would have further limited the generalizability of 459 
results and potentially increase the risk of the threshold bias for a higher sensitivity at 460 
the expense of a lower specificity.(9) 461 
Finally, as with any meta-analysis, limitations to this method include heterogeneity in 462 
between studies and presence of publication bias. An in-depth discussion of limitations 463 








This systematic review and meta-analysis concludes that pCMR is superior to DSE in 467 
the diagnosis of relevant coronary artery stenosis in patients with an intermediate pre-468 
test probability of CAD. Patients in this cohort might benefit from primary pCMR 469 
assessment for risk stratification and to guide further invasive procedures.  470 
 471 
Clinical Competencies 472 
The evaluation of the accuracy of pCMR and DSE for diagnosis of significant coronary 473 
artery stenosis is relevant for the appropriate management and risk stratification of 474 
patients with suspected or stable CAD. Erroneous interpretations of hemodynamic 475 
relevance of stenosis can lead to clinically unnecessary revascularizations without any 476 
prognostic benefit to patients. Moreover, the underlying systematic review revealed a 477 
discrepancy between the absolute amount of evidence on DSE assessment for CAD 478 
and its significance regarding valide risk stratification and adaquate reference 479 
methodes, which limits their clinical value. 480 
 481 
Translational Outlook 482 
Even though pCMR presented here as the superior non-invasive method, this meta-483 
analysis does not qualify to comment on the general validity of its superiority in the 484 
assessment of CAD. A comparative cost-effectiveness analysis is needed, in order to 485 
assess efficiency. It may be possible, in certain patient groups, that pCMR has some 486 
diagnostic advantages over FFR but this was outside the scope of the current review. 487 
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Figure titles and legends 653 
 654 
 655 
Figure 1: Flowchart of study selection process. Kamiya et al. (2014) reported results 656 
for DSE and pCMR, so that it contributed with two sets of data to the quantitative, but 657 









Figure 2: Forrest plot for pCMR with sensitivity (left) and specificity (right) 
estimates. CI = confidence intervall. I2 = the percentage of variation across studies 









Figure 3: Forrest plot for DSE with sensitivity (left) and specificity (right) estimates. CI 661 
= confidence intervall. I2 = the percentage of variation across studies that is due to 662 
heterogeneity rather than chance. Q = Cochran’s Q measure of heterogeneity. 663 
 664 In r
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Figure 4: Central Illustration. Likelihood ranges at which the respective tests can 666 
rule-in (green) and rule-out (red) obstructive CAD. (A) Respective likelihood ranges at 667 
a intermediate risk of CAD (50% PrTP). (B) Respective likelihood ranges at a low (25% 668 
PrTP) and (C) a high risk (75% PrTP) of obstructive CAD. Note that only pCMR can 669 
rule-out relevant CAD (defined as PoTP < 15%) at an intermediate PrTP. CAD = 670 
coronary artery disease. PrTP = pre-test probability. PoTP = post-test-probability. 671 
  672 
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   673 
Figure 5: Univariable meta-regression and subgroup analysis of (A) pCMR and (B) 674 




   678 
Figure 6: The vertical axis displays the inverse of the square root of the effective 679 
sample size (1/root(ESS)). The horizontal axis displays the DOR. p values < 0.10 680 
indicate non-symmetrical funnel shapes and is suggestive of publication bias. (A) 681 
pCMR. (B) DSE.  682 
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Tables  683 
 684 
Table 1: Study characteristics. n/s = not stated. S = suspected. S&K = suspected & 685 
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 pCMR DSE 
Parameter    Estimate    95% CI    Estimate    95% CI 
Number of studies included 39  9  
Number of patients included 4.115  652  
Sensitivity 
   Q 














   Q 













Positive LR 5.5 [4.7–6.5] 6.3 [3.8–10.4] 
Negative LR 0.14 [0.12–0.18] 0.31 [0.21–0.46] 
DOR  38 [29–49] 20 [9-46] 
Positive post-test probability 
   at 25% pre-test 
   at 50% pre-test 










Negative post-test probability 
   at 25% pre-test 
   at 50% pre-test 










Deek’s funnel plot p value 0.95  0.74  
Table 2: Summary of findings table. DOR = diagnostic odds ratio. I2 = the percentage 688 
of variation across studies that is due to heterogeneity rather than chance. LR = 689 
likelihood ratio. Q = Cochran’s Q measure of heterogeneity.  690 
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Search strategy  2 
 3 
Medline (Ovid)   
# Search term Hits 
1 exp Echocardiography/ 123.503  
2 echocardio*.tw 134.966  
3 echo-cardio*.tw 309  
4 1 or 2 or 3 178.142  
5 exp dobutamine/ 5.963  
6 Vasodilator Agents/ or Exercise Test/ or "Severity of Illness Index"/ or Stress, 
Pharmalogical/ or Myocardial Perfusion Imaging/ or Pharmacologic Stress 
Testing.mp 
316.330  
7 Stress/ or Echocardiography, Stress/ or stress-echo.mp 2.904  
8 5 or 6 or 7 322.058  
9 4 and 8 18.455  
10 exp Magnetic Resonance Imaging/ 395.786  
11 ((magnetic Resonance or MR or NMR) adj3 (Imag* or tomograph* or scan*)).tw 258.908  
12 (MRI or MRIs or NMRI or NMRIS).tw 207.802  
13 10 or 11 or 12 527.215  
14 exp Myocardial Perfusion Imaging/ 3.591  
15 exp Adenosine/ 48.846  
16 Magnetic Resonance Angiography/ or Contrast Media/ or Magnetic Resonance 
Imaging, Stress/ or stress-mr*.mp 
97.577  
17 adenos*.tw 119.593  
18 regadenos*.tw 264  
19 (stress* adj3 MR*).tw 1.924  
20 6 or 14 or 15 or 16 or 17 or 18 or 19 550.622  
21 13 and 20 61.316  
22 exp Sensitivity/ 529.160  
23 exp Specificity/ 529.160  
24 (Sensitivity and Specificity).mp [mp=title, abstract, original title, name of 
substance word, subject heading word, floating sub-heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier, synonyms] 
450.001  
25 22 or 23 or 24 632.370  
26 Coronary Artery Disease/ or Coronary Disease/ or Coronary Disease/ or 
Myocardial Ischemia/ 
213.108  
27 exp Coronary Angiography/ 59.295  
28 (PTA or PTCA).tw 14.305  
29 ((percutaneous coronary or coronary) adj6 (angiography or angioplasty or 
angio)).tw 
47.386  
30 ((transluminal or trans-luminal) adj6 coronary).tw 7.524  
31 angioplast*.tw 41.192  
32 26 or 27 or 28 or 29 or 30 or 31 288.939  
33 25 and 32 23.013  
34 9 and 33 2.045  
35 21 and 33 1.210  
36 34 or 35 3.145  
 4 
  5 
EMBASE (Ovid)   
# Search term Hits 
1 exp Echocardiography/ 297.149  
2 echocardio*.tw 225.253  
3 echo-cardio*.tw 762  
4 1 or 2 or 3 334.144  
5 exp dobutamine/ 23.015  
6 Vasodilator Agents/ or Exercise Test/ or "Severity of Illness Index"/ or Stress, 
Pharmalogical/ or Myocardial Perfusion Imaging/ or Pharmacologic Stress 
Testing.mp 
101.339  
7 Stress/ or Echocardiography, Stress/ or stress-echo.mp 140.126  
8 5 or 6 or 7 255.574  
9 4 and 8 22.812  
10 exp Magnetic Resonance Imaging/ 823.611  
11 ((magnetic Resonance or MR or NMR) adj3 (Imag* or tomograph* or scan*)).tw 327.281  
12 (MRI or MRIs or NMRI or NMRIS).tw 355.343  
13 10 or 11 or 12 887.169  
14 exp Myocardial Perfusion Imaging/ 7.670  
15 exp Adenosine/ 39.640  
16 Magnetic Resonance Angiography/ or Contrast Media/ or Magnetic Resonance 
Imaging, Stress/ or stress-mr*.mp 
86.098  
17 adenos*.tw 138.547  
18 regadenos*.tw 738  
19 (stress* adj3 MR*).tw 2.705  
20 6 or 14 or 15 or 16 or 17 or 18 or 19 334.784  
21 13 and 20 54.509  
22 exp Sensitivity/ 0  
23 exp Specificity/ 0  
24 (Sensitivity and Specificity).mp [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword, floating subheading word, candidate term word] 
435.546  
25 22 or 23 or 24 435.546  
26 Coronary Artery Disease/ or Coronary Disease/ or Coronary Disease/ or 
Myocardial Ischemia/ 
216.654  
27 exp Coronary Angiography/ 13.638  
28 (PTA or PTCA).tw 19.835  
29 ((percutaneous coronary or coronary) adj6 (angiography or angioplasty or 
angio)).tw 
72.442  
30 ((transluminal or trans-luminal) adj6 coronary).tw 8.692  
31 angioplast*.tw 56.730  
32 26 or 27 or 28 or 29 or 30 or 31 312.896  
33 25 and 32 12.242  
34 9 and 33 1.473  
35 21 and 33 833  
36 34 or 35 2.135  
 6 
  7 
Cochrane Library (Wiley Online)   
# Search term Hits 
#1 MeSH descriptor: [Echocardiography] explode all trees 4.234 
#2 echocardio*:ti,ab,kw  (Word variations have been searched) 10.809 
#3 echo-cardio*:ti,ab,kw  (Word variations have been searched) 27 
#4 #1 or #2 or #3  10.822 
#5 MeSH descriptor: [Dobutamine] explode all trees 531 
#6 Vasodilator Agents or Exercise Test or Severity of Illness Index or Stress, 
Pharmalogical or Myocardial Perfusion Imaging:ti,ab,kw  (Word variations have 
been searched) 
53.042 
#7 MeSH descriptor: [Exercise Test] explode all trees 8.075 
#8 Stress or Echocardiography, Stress or stress-echo:ti,ab,kw  (Word variations 
have been searched) 
40.847 
#9 #5 or #6 or #7 or #8  89.889 
#10 #4 and #9  2.648 
#11 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees 8.073 
#12 ((magnetic Resonance or MR or NMR) near/3 (Imag* or tomograph* or 
scan*)):ti,ab,kw  (Word variations have been searched) 
19.963 
#13 MRI or MRIs or NMRI or NMRIS:ti,ab,kw  (Word variations have been searched) 11.744 
#14 #11 or #12 or #13  22.504 
#15 MeSH descriptor: [Myocardial Perfusion Imaging] explode all trees 185 
#16 MeSH descriptor: [Adenosine] explode all trees 1.405 
#17 Magnetic Resonance Angiography or Contrast Media or Magnetic Resonance 
Imaging, Stress or stress-mr*:ti,ab,kw  (Word variations have been searched) 
6.685 
#18 adenos*:ti,ab,kw  (Word variations have been searched) 5.128 
#19 regadenos*:ti,ab,kw  (Word variations have been searched) 104 
#20 stress* near/3 MR*:ti,ab,kw  (Word variations have been searched) 52 
#21 #6 or #15 or #16 or #17 or #18 or #19 or #20  64.202 
#22 #14 and #21  3.545 
#23 MeSH descriptor: [Sensitivity and Specificity] explode all trees 19.521 
#24 Sensitivity:ti,ab,kw  (Word variations have been searched) 50.913 
#25 Specificity:ti,ab,kw  (Word variations have been searched) 23.920 
#26 #23 or #24 or #25  60.373 
#27 MeSH descriptor: [Coronary Angiography] explode all trees 4.264 
#28 Coronary Artery Disease or Coronar Disease or Coronary Disease or Myocardial 
Ischemia:ti,ab,kw  (Word variations have been searched) 
31.573 
#29 ((percutaneous coronary or coronary) near/6 (angiography or angioplasty or 
angio)):ti,ab,kw  (Word variations have been searched) 
10.607 
#30 ((transluminal or trans-luminal) near/6 coronary):ti,ab,kw  (Word variations have 
been searched) 
1.481 
#31 angioplast*:ti,ab,kw  (Word variations have been searched) 7.915 
#32 (PTA or PTCA):ti,ab,kw  (Word variations have been searched) 1.719 
#33 #27 or #28 or #29 or #30 or #31 or #32  38.469 
#34 #26 and #33  3.060 
#35 #10 and #34  234 
#36 #22 and #34  131 
#37 #35 or #36  351 
 8 
  9 
Review-specific tailoring of QUADAS 10 
 11 
# Topic Description Yes unclear No 
1 Representative spectrum Was the spectrum of patients representative of the patients 
who will receive the test in practice? 
43 1 3 
2 Acceptable reference 
standard 
Is the reference standard likely to classify the target 
condition correctly?  
47 0 0 
3 Acceptable delay between 
tests 
Is the time period between reference standard and index 
test short enough to be reasonably sure that the target 
condition did not change between the two tests?  
33 10 4 
4 Partial verification avoided Did the whole sample or a random selection of the sample, 
receive verification using the intended reference standard? 
38 4 5 
5 Differential verification 
avoided 
Did patients receive the same reference standard 
irrespective of the index test result? 
46 0 1 
6 Incorporation avoided Was the reference standard independent of the index test 
(i.e. the index test did not form part of the reference 
standard)?  
47 0 0 
7 Index test results blinded Were the reference standard results interpreted without 
knowledge of the results of the index test?  
31 14 2 
8 Reference standard results 
blinded 
Were the index test results interpreted without knowledge 
of the results of the reference standard?  
35 12 0 
9 Relevant clinical 
information 
Were the same clinical data available when test results 
were interpreted as would be available when the test is 
used in practice?  
7 20 20 
10 Uninterpretable results 
reported? 
Were uninterpretable/ intermediate test results reported?  34 12 1 




Supplementary material Figure A1: QUADAS tool assessment for all studies 15 
included in the meta-analysis. 16 
17 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 pCMR DSE 
Parameter    Estimate    Estimate 
E(logitSe) 1.9777 0.9521 
E(logitSp) 1.6648 2.0472 
Var(logitSe) 0.2785 0.3798 
Var(logitSp) 0.2569 0.2476 
Corr(logits) -0.0033 0.0259 
Supplementary material Table 1: Covariance matrix of parameter estimates among 20 
pCMR and DSE studies. E(logitSe) summary estimate for logit(sensitivity). E(logitSp) 21 
summary estimate for logit(specificity) and Corr(logits) their covariance. Var(logitSe) 22 
variances of the random effects for logit(sensitivity), Var(logitSp) of logit(specificity). 23 
 24 
Influence of outlier detection analysis 25 
 26 
Supplementary material Figure A2: Influence of outlier analysis for sMRI studies with 27 
a) Goodness-of-Fit b) Bivariate Normality c) Influence analysis and d) Outlier detection. 28 
A) Displays the Deviance residual on the y-axis and the normal quantile on the x-axis 29 
attesting an exceptional good fit of studies. B) Displays the Mahalano D-squared value 30 
on the y-axis and the Chi-squared quantile on the x-axis attesting normal distribution 31 
of sMRI studies. C) Displays the Cock’s distance on the y-axis and the study number 32 
on the x-axis. Indicating a low influence of the three outliers (yellow) to the overall study 33 
results. D) Displays the standardized residual diseased on the y- and healthy on the x-34 
axis with the three outliers in yellow and their relative position on the graph towards 35 
the overall study mean (black square in the graph centre).  36 
 37 
 38 
Supplementary material Figure A3: Influence of outlier analysis for DSE studies with 39 
a) Goodness-of-Fit b) Bivariate Normality c) Influence analysis and d) Outlier detection. 40 
A) Displays the Deviance residual on the y-axis and the normal quantile on the x-axis 41 
attesting an expectable good fit of studies. B) Displays the Mahalano D-squared value 42 
on the y-axis and the Chi-squared quantile on the x-axis attesting a roughly normal 43 
distribution of DSE studies. C) Displays the Cock’s distance on the y-axis and the study 44 
number on the x-axis. Indicating a somewhat relevant influence of the outlier study 45 
(yellow) to the overall study results. D) Displays the standardized residual diseased on 46 
the y- and healthy on the x-axis with the outlier in yellow and its relative position on the 47 
graph towards the overall study mean (black square in the graph centre).   48 
Moses-Littenberg SROC analysis 49 
A B 
   50 
Supplementary material Figure A4: The vertical axis of the plots depicts sensitivity. 51 
The horizontal axis the specificity. The SROC curves (solid black) display the 52 
sensitivity as well as specificity of the individual studies with a 95% prediction (dotted 53 
line) and confidence (dashed line) region, complemented by the summary point in red 54 
for A sMRI and B DSE. The area under the SROC curve for sMRI is bigger as 55 
compared to the one of DSE (0.93 vs 0.89).  56 
In depth analysis of across study variance 57 
The outlier analysis depicted in Supplementary material Figure A2 and A3 implement 58 
an influence of one study (Klem 2008 - Cook’s distance 2.7) to the pCMR results, and 59 
for one study (Santoro 1998 – Cook’s distance 4.8) to the DSE results. The magnitude 60 
of heterogeneity can also be understood by the size of the prediction region in the 61 
SROC plot, (Supplementary material Figure A4) which attests pCMR studies a smaller 62 
degree of heterogeneity compared to DSE studies. The size of the prediction region 63 
on the SROC plot for pCMR (0.29; 95 % CI 0.11–0.77) was significantly smaller 64 
compared to DSE (1.07; 95 % CI 0.27–4.19; p<0.01). The sensitivity and specificity at 65 
this point is calculated by an “inverse transformation of the logit estimates to give a 66 
sensitivity and specificity”(1) of 0.88 and 0.84 in pCMR, and 0.72 and 0.89 in DSE 67 
studies, respectively. The significantly larger 95% confidence region in the SROC plot 68 
of DSE studies implies more uncertainty of the results and therefore a greater influence 69 
of the outlayer study. 70 
Varying sample sizes of sensitivity and specificity measures in DSE studies as reasons 71 
for heterogeneity seem implausible since precision measures, such as the SROC plot 72 
give the impression of a broader heterogeneity of results. 73 
In this meta-analysis only studies with a specifically defined threshold of significant 74 
coronary artery stenosis were included, which are then not randomly distributed 75 
accordingly. Nevertheless, it must be acknowledged that even a pre-defined cut-off 76 
value does not preclude some variance in the actual cut-off through differences in 77 
calibration, in the technical equipment, in the implementation, as well as between 78 
observers, causing additional heterogeneity of results.22 It is therefore reasonable to 79 
estimate both, SORC and HSROC curves, as they may complement each other in the 80 
provision of clinically meaningful results.22 81 
 82 
Study limitations 83 
The subgroup analyses demonstrated most study characteristics did not significantly 84 
affect the diagnostic performance of pCMR and DSE. However, the power to detect 85 
relevant differences between subgroups may have been limited by the number of 86 
studies in specific subgroups, which tested DSE. The majority of studies included a 87 
mixture of patients with known and/or suspected CAD. Consequently, the subgroup 88 
analysis of CAD status (suspected or known) was limited due to unclear distinction of 89 
results in assorted cohorts. This meta-analysis suggests that the diagnostic accuracy 90 
of pCMR and DSE is not influenced by including patients with known CAD as far as 91 
the data allow to comment.  92 
Another limitation of meta-analyses in general is the dependence on the original 93 
publications in terms of quality and details of the reported data. Data on meaningful 94 
cardio-vascular risk factors, such as prevalence of smoking, hyperlipidaemia and 95 
family history, were generally poorly available and therefore not included in the 96 
analysis. Solely data on the prevalence of hypertension and diabetes were widely 97 
available. A more sophisticated cardiovascular risk assessment would have allowed to 98 
further assess heterogeneity among studies and could have increased in depth 99 
understanding of discrepancies in different diagnostic accuracy measures. 100 
The heterogeneity across studies regarding the assessment methods, imaging 101 
techniques, setting, contrast agent, stressors used, patient inclusion criteria, CAD 102 
prevalence and percentage of male patients is a limitation of meta-analyses of DTAs. 103 
Although a specific CAD cut-off definitions and patient inclusion criteria were enabled, 104 
sample size limitations did not allow a subgroup analyses of all underlying factors. In 105 
this meta-analysis a random effect model was used, adjusting estimates and 106 
confidence intervals to the between-study variation. Nonetheless, the heterogeneity 107 
across studies remains a considerable limitation as stressed out above.  108 
Additionally, one has to consider that the tested MPI examinations can also reveal 109 
functional information (e.g. left ventricular ejection fraction, presence of regional 110 
contraction abnormalities, presence of myocardial scars), more than an invasive 111 
assessment of coronary stenosis by CCA or a SPECT or PET image alone. The 112 
present analysis does not take the possible bias of these incidental parameters on the 113 
interpretation of the assessed MPI methods into account. Nevertheless, this 114 
information will also be present in the clinical evaluation of these MPIs and will 115 
therefore not increment their diagnostic accuracy. Noteworthy is also the fact that in 116 
the clinical routine at least a fraction of patients will be unsuitable for a sMRI 117 
assessment due to claustrophobia, BMI or severe renal failure. Like-wise, DSE can 118 
only be performed in presence of an adequate acoustic window, which limits the 119 
eligibility of some patients. Therefore, incompatible patients were excluded in the 120 
original papers, which in consequence, could influence the diagnostic accuracy of this 121 
meta-analysis. Sadly, there was no sufficient reporting of these information by the 122 
included studies to further elaborate this issue in a subgroup-analysis.  123 
On a more in-depth review, did this meta-analysis incorporate results on per-patient as 124 
well as on per-vessel data. Thereby, the per-patient data is more valuable since we 125 
treat individual patients and not individual coronaries. In theory, it is more plausible 126 
that the sensitivity of per-person level data is higher, however, the specificity is 127 
believed to be inferior. In practice however, the meta-regression analysis to this 128 
assessment could not confirm this theory and found the diagnostic accuracy in regards 129 
to per-person or –vessel data indifferent. Sensitivity 0.88 (95% CI: 0.86-0.91) vs 0.86 130 
(95% CI: 0.81-0.91) and specificity 0.84 (95% CI: 0.81-0.88) vs 0.83 (95% CI: 0.78-131 
0.88, p < 0.01). 132 
The significant slope coefficient in the Deek’s funnel plot (Figure 6 b) of DSE studies 133 
is suggestive of a significant small study bias. It is possible that small studies with a 134 
low diagnostic performance of DSE remained unpublished. Consequently, the 135 
presented diagnostic accuracy of DSE, which is still inferior to sMRI, could in fact be 136 
overestimated. 137 
 138 
  139 
References of included studies 140 
1. Hoffmann R, Lethen H, Kleinhans E, Weiss M, Flachskampf FA and Hanrath P. 141 
Comparative evaluation of bicycle and dobutamine stress echocardiography with 142 
perfusion scintigraphy and bicycle electrocardiogram for identification of coronary 143 
artery disease. American Journal of Cardiology. 1993;72:555-559. 144 
2. Dagianti A, Penco M, Agati L, Sciomer S, Dagianti A, Rosanio S and Fedele F. 145 
Stress echocardiography: comparison of exercise, dipyridamole and dobutamine 146 
in detecting and predicting the extent of coronary artery disease.[Erratum appears 147 
in J Am Coll Cardiol 1995 Oct;26(4):1114]. Journal of the American College of 148 
Cardiology. 1995;26:18-25. 149 
3. Sochowski RA, Yvorchuk KJ, Yang Y, Rattes MF and Chan KL. Dobutamine and 150 
dipyridamole stress echocardiography in patients with a low incidence of severe 151 
coronary artery disease. Journal of the American Society of Echocardiography : 152 
official publication of the American Society of Echocardiography. 1995;8:482-487. 153 
4. Bartunek J, Marwick TH, Rodrigues AC, Vincent M, Van Schuerbeeck E, Sys SU 154 
and de Bruyne B. Dobutamine-induced wall motion abnormalities: correlations with 155 
myocardial fractional flow reserve and quantitative coronary angiography. Journal 156 
of the American College of Cardiology. 1996;27:1429-36. 157 
5. Santoro GM, Sciagra R, Buonamici P, Consoli N, Mazzoni V, Zerauschek F, Bisi 158 
G and Fazzini PF. Head-to-head comparison of exercise stress testing, 159 
pharmacologic stress echocardiography, and perfusion tomography as first-line 160 
examination for chest pain in patients without history of coronary artery disease. 161 
Journal of Nuclear Cardiology. 1998;5:19-27. 162 
6. Rieber J, Jung P, Erhard I, Koenig A, Hacker M, Schiele TM, Segmiller T, Stempfle 163 
HU, Theisen K, Siebert U and Klauss V. Comparison of pressure measurement, 164 
dobutamine contrast stress echocardiography and SPECT for the evaluation of 165 
intermerdiate coronary stenoses. The COMPRESS trial. International Journal of 166 
Cardiovascular Interventions. 2004;6:142-147. 167 
7. Jung PH, Rieber J, Stork S, Hoyer C, Erhardt I, Nowotny A, Voelker W, 168 
Weidemann F, Ertl G, Klauss V and Angermann CE. Effect of contrast application 169 
on interpretability and diagnostic value of dobutamine stress echocardiography in 170 
patients with intermediate coronary lesions: comparison with myocardial fractional 171 
flow reserve. European heart journal. 2008;29:2536-43. 172 
8. Kamiya K, Sakakibara M, Asakawa N, Yoshitani T, Iwano H, Komatsu H, Naya M, 173 
Chiba S, Yamada S, Manabe O, Kikuchi Y, Oyama-Manabe N, Oba K and Tsutsui 174 
H. Cardiac magnetic resonance performs better in the detection of functionally 175 
significant coronary artery Stenosis compared to single-photon emission 176 
computed Tomography and Dobutamine stress echocardiography. Circulation 177 
Journal. 2014;78:2468-2476. 178 
9. Kim MN, Kim SA, Kim YH, Hong SJ, Park SM, Shin MS, Kim MA, Hong KS, Shin 179 
GJ and Shim WJ. Head to head comparison of stress echocardiography with 180 
exercise electrocardiography for the detection of coronary artery stenosis in 181 
women. Journal of Cardiovascular Ultrasound. 2016;24:135-143. 182 
10. Nagel E, Klein C, Paetsch I, Hettwer S, Schnackenburg B, Wegscheider K and 183 
Fleck E. Magnetic resonance perfusion measurements for the noninvasive 184 
detection of coronary artery disease. Circulation. 2003;108:432-437. 185 
11. Paetsch I, Jahnke C, Wahl A, Gebker R, Neuss M, Fleck E and Nagel E. 186 
Comparison of dobutamine stress magnetic resonance, adenosine stress 187 
magnetic resonance, and adenosine stress magnetic resonance perfusion. 188 
Circulation. 2004;110:835-842. 189 
12. Pons Llado G, Carreras F, Leta R, Pujadas S and Garcia Picart J. Assesment of 190 
myocardial perfusion by cardiovascular magnetic resonance: Comparison with 191 
coronary angiography. [Spanish]. Revista espanola de cardiologia. 2004;57:388-192 
395. 193 
13. Wolff SD, Schwitter J, Coulden R, Friedrich MG, Bluemke DA, Biederman RW, 194 
Martin ET, Lansky AJ, Kashanian F, Foo TKF, Licato PE and Comeau CR. 195 
Myocardial first-pass perfusion magnetic resonance imaging: A multicenter dose-196 
ranging study. Circulation. 2004;110:732-737. 197 
14. Plein S, Radjenovic A, Ridgway JP, Barmby D, Greenwood JP, Ball SG and 198 
Sivananthan MU. Coronary artery disease: Myocardial perfusion MR imaging with 199 
sensitivity encoding versus conventional angiography. Radiology. 2005;235:423-200 
430. 201 
15. Klem I, Heitner JF, Shah DJ, Sketch Jr MH, Behar V, Weinsaft J, Cawley P, Parker 202 
M, Elliott M, Judd RM and Kim RJ. Improved Detection of Coronary Artery Disease 203 
by Stress Perfusion Cardiovascular Magnetic Resonance With the Use of Delayed 204 
Enhancement Infarction Imaging. Journal of the American College of Cardiology. 205 
2006;47:1630-1638. 206 
16. Pilz G, Bernhardt P, Klos M, Ali E, Wild M and Hofling B. Clinical implication of 207 
adenosine-stress cardiac magnetic resonance imaging as potential gatekeeper 208 
prior to invasive examination in patients with AHA/ACC class II indication for 209 
coronary angiography. Clinical Research in Cardiology. 2006;95:531-538. 210 
17. Costa MA, Shoemaker S, Futamatsu H, Klassen C, Angiolillo DJ, Nguyen M, 211 
Siuciak A, Gilmore P, Zenni MM, Guzman L, Bass TA and Wilke N. Quantitative 212 
magnetic resonance perfusion imaging detects anatomic and physiologic coronary 213 
artery disease as measured by coronary angiography and fractional flow reserve. 214 
Journal of the American College of Cardiology. 2007;50:514-22. 215 
18. Kuhl HP, Katoh M, Buhr C, Krombach GA, Hoffmann R, Rassaf T, Neizel M, 216 
Buecker A and Kelm M. Comparison of Magnetic Resonance Perfusion Imaging 217 
Versus Invasive Fractional Flow Reserve for Assessment of the Hemodynamic 218 
Significance of Epicardial Coronary Artery Stenosis. American Journal of 219 
Cardiology. 2007;99:1090-1095. 220 
19. Merkle N, Wohrle J, Grebe O, Nusser T, Kunze M, Kestler HA, Kochs M and 221 
Hombach V. Assessment of myocardial perfusion for detection of coronary artery 222 
stenoses by steady-state, free-precession magnetic resonance first-pass imaging. 223 
Heart. 2007;93:1381-1385. 224 
20. Klem I, Greulich S, Heitner JF, Kim H, Vogelsberg H, Kispert EM, Ambati SR, 225 
Bruch C, Parker M, Judd RM, Kim RJ and Sechtem U. Value of Cardiovascular 226 
Magnetic Resonance Stress Perfusion Testing for the Detection of Coronary Artery 227 
Disease in Women. JACC: Cardiovascular Imaging. 2008;1:436-445. 228 
21. Meyer C, Strach K, Thomas D, Litt H, Nahle CP, Tiemann K, Schwenger U, Schild 229 
HH and Sommer T. High-resolution myocardial stress perfusion at 3 T in patients 230 
with suspected coronary artery disease. European radiology. 2008;18:226-233. 231 
22. Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, 232 
Cunningham T, Bezlyak V, Ford I, Dargie HJ and Oldroyd KG. Validation of 233 
magnetic resonance myocardial perfusion imaging with fractional flow reserve for 234 
the detection of significant coronary heart disease. Circulation. 2009;120:2207-235 
2213. 236 
23. Klumpp BD, Seeger A, Doesch C, Doering J, Hoevelborn T, Kramer U, Fenchel M, 237 
Gawaz MP, Claussen CD and Miller S. High resolution myocardial magnetic 238 
resonance stress perfusion imaging at 3 T using a 1 M contrast agent. European 239 
radiology. 2010;20:533-541. 240 
24. Scheffel H, Stolzmann P, Alkadhi H, Azemaj N, Plass A, Baumueller S, Desbiolles 241 
L, Leschka S, Kozerke S, Falk V, Boesiger P, Wyss C, Marincek B and Donati OF. 242 
Low-dose CT and cardiac MR for the diagnosis of coronary artery disease: 243 
Accuracy of single and combined approaches. International Journal of 244 
Cardiovascular Imaging. 2010;26:579-590. 245 
25. Kirschbaum SW, Springeling T, Rossi A, Duckers E, Gutierrez-Chico JL, Regar E, 246 
De Feyter PJ and Van Geuns RJM. Comparison of adenosine magnetic resonance 247 
perfusion imaging with invasive coronary flow reserve and fractional flow reserve 248 
in patients with suspected coronary artery disease. International Journal of 249 
Cardiology. 2011;147:184-186. 250 
26. Lockie T, Ishida M, Perera D, Chiribiri A, De Silva K, Kozerke S, Marber M, Nagel 251 
E, Rezavi R, Redwood S and Plein S. High-resolution magnetic resonance 252 
myocardial perfusion imaging at 3.0-Tesla to detect hemodynamically significant 253 
coronary stenoses as determined by fractional flow reserve. Journal of the 254 
American College of Cardiology. 2011;57:70-5. 255 
27. Huber A, Sourbron S, Klauss V, Schaefer J, Bauner KU, Schweyer M, Reiser M, 256 
Rummeny E and Rieber J. Magnetic resonance perfusion of the myocardium: 257 
semiquantitative and quantitative evaluation in comparison with coronary 258 
angiography and fractional flow reserve. Investigative Radiology. 2012;47:332-8. 259 
28. Jogiya R, Kozerke S, Morton G, De Silva K, Redwood S, Perera D, Nagel E and 260 
Plein S. Validation of dynamic 3-dimensional whole heart magnetic resonance 261 
myocardial perfusion imaging against fractional flow reserve for the detection of 262 
significant coronary artery disease. Journal of the American College of Cardiology. 263 
2012;60:756-765. 264 
29. Khoo JP, Grundy BJ, Steadman CD, Sonnex EP, Coulden RA and McCann GP. 265 
Stress cardiovascular MR in routine clinical practice: Referral patterns, accuracy, 266 
tolerance, safety and incidental findings. British Journal of Radiology. 267 
2012;85:e851-e857. 268 
30. Manka R, Paetsch I, Kozerke S, Moccetti M, Hoffmann R, Schroeder J, Reith S, 269 
Schnackenburg B, Gaemperli O, Wissmann L, Wyss CA, Kaufmann PA, Corti R, 270 
Boesiger P, Marx N, Luscher TF and Jahnke C. Whole-heart dynamic three-271 
dimensional magnetic resonance perfusion imaging for the detection of coronary 272 
artery disease defined by fractional flow reserve: Determination of volumetric 273 
myocardial ischaemic burden and coronary lesion location. European heart 274 
journal. 2012;33:2016-2024. 275 
31. Bernhardt P, Walcher T, Buckert D, Woehrle J and Rottbauer W. Adenosine blood 276 
oxygen level dependent T2-weighted imaging correlates to fractional flow reserve. 277 
European heart journal. 2013;1):1021. 278 
32. Bettencourt N, Chiribiri A, Schuster A, Ferreira N, Sampaio F, Duarte R, Santos L, 279 
Melica B, Rodrigues A, Braga P, Teixeira M, Simoes L, Leite-Moreira A, Silva-280 
Cardoso J, Nagel E, Portugal P and Gama V. Cardiac magnetic resonance 281 
myocardial perfusion imaging for detection of functionally significant obstructive 282 
coronary artery disease: A prospective study. International Journal of Cardiology. 283 
2013;168:765-773. 284 
33. Chiribiri A, Hautvast GLTF, Lockie T, Schuster A, Bigalke B, Olivotti L, Redwood 285 
SR, Breeuwer M, Plein S and Nagel E. Assessment of coronary artery stenosis 286 
severity and location: Quantitative analysis of transmural perfusion gradients by 287 
high-resolution MRI versus FFR. JACC: Cardiovascular Imaging. 2013;6:600-609. 288 
34. Ebersberger U, Makowski MR, Schoepf UJ, Platz U, Schmidtler F, Rose J, Kessel 289 
A, Roth P, Antoni D, Schnackenburg B, Helmberger T, Rieber J, Hoffmann E and 290 
Leber AW. Magnetic resonance myocardial perfusion imaging at 3.0 Tesla for the 291 
identification of myocardial ischaemia: comparison with coronary catheter 292 
angiography and fractional flow reserve measurements. European heart journal 293 
cardiovascular Imaging. 2013;14:1174-80. 294 
35. Groothuis JGJ, Beek AM, Brinckman SL, Meijerink MR, Van Den Oever MLP, 295 
Hofman MBM, Van Kuijk C and Van Rossum AC. Combined non-invasive 296 
functional and anatomical diagnostic work-up in clinical practice: The magnetic 297 
resonance and computed tomography in suspected coronary artery disease 298 
(MARCC) study. European heart journal. 2013;34:1990-1998. 299 
36. Pereira E, Bettencourt N, Ferreira N, Schuster A, Chiribiri A, Primo J, Teixeira M, 300 
Simoes L, Leite-Moreira A, Silva-Cardoso J, Gama V and Nagel E. Incremental 301 
value of adenosine stress cardiac magnetic resonance in coronary artery disease 302 
detection. International Journal of Cardiology. 2013;168:4160-4167. 303 
37. Walcher T, Ikuye K, Rottbauer W, Wohrle J and Bernhardt P. Is contrast-enhanced 304 
cardiac magnetic resonance imaging at 3 T superior to 1.5 T for detection of 305 
coronary artery disease? International Journal of Cardiovascular Imaging. 306 
2013;29:355-361. 307 
38. Ponte M, Bettencourt N, Pereira E, Ferreira ND, Chiribiri A, Schuster A, 308 
Albuquerque A, Gama V and Nagel E. Anatomical versus functional assessment 309 
of coronary artery disease: direct comparison of computed tomography coronary 310 
angiography and magnetic resonance myocardial perfusion imaging in patients 311 
with intermediate pre-test probability. The international journal of cardiovascular 312 
imaging. 2014;30:1589-97. 313 
39. Greulich S, Steubing H, Birkmeier S, Grun S, Bentz K, Sechtem U and Mahrholdt 314 
H. Impact of arrhythmia on diagnostic performance of adenosine stress CMR in 315 
patients with suspected or known coronary artery disease. Journal of 316 
Cardiovascular Magnetic Resonance. 2015;17 (1) (no pagination). 317 
40. Manka R, Gebker R, Wissmann L, Jogiya R, Motwani M, Frick M, Reinartz SD, 318 
Schnackenburg B, Nagel E, Plein S and Kozerke S. Multicenter evaluation of 319 
dynamic three-dimensional whole-heart myocardial perfusion imaging for the 320 
detection of coronary artery disease defined by fractional flow reserve. Journal of 321 
Cardiovascular Magnetic Resonance. 2013;1):190-191. 322 
41. Pan J, Huang S, Lu Z, Li J, Wan Q, Zhang J, Gao C, Yang X and Wei M. 323 
Comparison of myocardial transmural perfusion gradient by magnetic resonance 324 
imaging to fractional flow reserve in patients with suspected coronary artery 325 
disease. American Journal of Cardiology. 2015;115:1333-40. 326 
42. Ripley DP, Motwani M, Brown JM, Nixon J, Everett CC, Bijsterveld P, Maredia N, 327 
Plein S and Greenwood JP. Individual component analysis of the multi-parametric 328 
cardiovascular magnetic resonance protocol in the CE-MARC trial. Journal of 329 
Cardiovascular Magnetic Resonance. 2015;17 (1) (no pagination). 330 
43. Papanastasiou G, Williams MC, Dweck MR, Alam S, Cooper A, Mirsadraee S, 331 
Newby DE and Semple SI. Quantitative assessment of myocardial blood flow in 332 
coronary artery disease by cardiovascular magnetic resonance: Comparison of 333 
Fermi and distributed parameter modeling against invasive methods. Journal of 334 
Cardiovascular Magnetic Resonance. 2016;18 (1) (no pagination). 335 
44. Foley JRJ, Kidambi A, Biglands JD, Maredia N, Dickinson CJ, Plein S and 336 
Greenwood JP. A comparison of cardiovascular magnetic resonance and single 337 
photon emission computed tomography (SPECT) perfusion imaging in left main 338 
stem or equivalent coronary artery disease: A CE-MARC substudy. Journal of 339 
Cardiovascular Magnetic Resonance. 2017;19 (1) (no pagination). 340 
45. Hamada S, Gotschy A, Wissmann L, Paetsch I, Jahnke C, Plein S, Gebker R, 341 
Oebel S, Alkadhi H, Marx N, Luscher TF, Kozerke S and Manka R. Multi-centre 342 
study of whole-heart dynamic 3D cardiac magnetic resonance perfusion imaging 343 
for the detection of coronary artery disease defined by fractional flow reserve: 344 
Gender based analysis of diagnostic performance. European Heart Journal 345 
Cardiovascular Imaging. 2017;18:1099-1106. 346 
46. Biglands JD, Ibraheem M, Magee DR, Radjenovic A, Plein S and Greenwood JP. 347 
Quantitative Myocardial Perfusion Imaging Versus Visual Analysis in Diagnosing 348 
Myocardial Ischemia: A CE-MARC Substudy. JACC: Cardiovascular Imaging. 349 
2018;11:711-718. 350 
47. Hsu LY, Jacobs M, Benovoy M, Ta AD, Conn HM, Winkler S, Greve AM, Chen 351 
MY, Shanbhag SM, Bandettini WP and Arai AE. Diagnostic Performance of Fully 352 
Automated Pixel-Wise Quantitative Myocardial Perfusion Imaging by 353 






Supplement material references 360 
1. Reitsma JB, Rutjes AWS, Whiting P, Vlassov VV, Leeflang MMG, Deeks JJ. 361 
Chapter 9: Assessing methodological quality. ,  Version , 2009. Available from: : 362 
The Cochrane Collaboration (2009) [cited 2018 June 29th]. 1.0.0:[Available from: 363 
http://srdta.cochrane.org/. 364 
 365 
